All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2012-000067-25 | Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia Protocol ALL-11: Protocol... | 2023-05-30 | due-trials |
Listed as ongoing, but also has a completion date | 2016-004674-17 | A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lympfoblastic leukemia ... | 2024-03-07 | bad-data |
Reported results | 2017-002738-22 | Double blind placebo controlled randomized intervention study to validate the beneficial effect of hydrocortisone on dexamethasone-induced neurobehavioral side effects in pediatric acute lymphoblastic... | 2021-03-27 | due-trials |
Exempt | 2018-000698-54 | A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric and young adult acute myeloid leukemia: the U-DANCE-anti-AML trial Een fase I/II onderzoek naar... | not-yet-due | |
Reported results | 2019-003713-33 | Diagnostic accuracy of neuroblastoma patient imaging with [18F]-mFBG PET-CT compared to [123]I-mIBG scanning Diagnostische nauwkeurigheid van beeldvorming van neuroblastoompatiënten met [18F]mFBG ... | 2021-08-02 | due-trials |
Exempt | 2020-000142-34 | A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092 | not-yet-due | |
Other | 2020-000508-13 | An open-label, randomized clinical trial on teicoplanin infection prophylaxis in pediatric patients with acute myeloid leukemia | not-yet-due | |
Reported results Terminated | 2020-000509-96 | Near-infrared fluorescence imaging using indocyanine green as an adjunct to improve standard-of-care sentinel lymph node procedure in pediatric patients with melanoma or sarcoma of head/neck/trunk, pa... | 2023-11-03 | due-trials |
Other | 2021-000213-16 | International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia | not-yet-due | |
Ongoing | 2021-002713-34 | A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors | not-yet-due | |
Other | 2021-003212-11 | A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML | not-yet-due | |
Ongoing | 2021-003311-26 | DAVINCY trial: optimal Duration of (fos)aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind placebo-controlled crossover randomized phase III trial’ D... | not-yet-due | |
Reported results | 2021-003388-90 | Prospective monitoring of immune response following COVID-19 vaccination in children with cancer | 2023-05-31 | due-trials |
Other | 2021-003398-79 | International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + Cycl... | not-yet-due | |
Ongoing | 2022-001811-16 | 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study 68Ga-SATO in pediatrische neuroblastoom patiënten; een verkennende, veiligheid, nie... | not-yet-due | |
Ongoing | 2022-002885-34 | CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium | not-yet-due |